Supernus Pharmaceuticals Inc (SUPN) : Falcon Point Capital reduced its stake in Supernus Pharmaceuticals Inc by 29.47% during the most recent quarter end. The investment management company now holds a total of 288,092 shares of Supernus Pharmaceuticals Inc which is valued at $6,358,190 after selling 120,387 shares in Supernus Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Supernus Pharmaceuticals Inc makes up approximately 1.07% of Falcon Point Capital’s portfolio.
Other Hedge Funds, Including , Smith Asset Management Group Lp reduced its stake in SUPN by selling 29,979 shares or 12.83% in the most recent quarter. The Hedge Fund company now holds 203,613 shares of SUPN which is valued at $4,493,739. Supernus Pharmaceuticals Inc makes up approx 0.13% of Smith Asset Management Group Lp’s portfolio.Thomson Horstmann Bryant Inc reduced its stake in SUPN by selling 24,400 shares or 41.65% in the most recent quarter. The Hedge Fund company now holds 34,188 shares of SUPN which is valued at $718,974. Supernus Pharmaceuticals Inc makes up approx 0.09% of Thomson Horstmann Bryant Inc’s portfolio.Farmers Merchants Investments Inc reduced its stake in SUPN by selling 51 shares or 13.25% in the most recent quarter. The Hedge Fund company now holds 334 shares of SUPN which is valued at $6,897.Franklin Street Advisors Inc Nc reduced its stake in SUPN by selling 8,200 shares or 7.16% in the most recent quarter. The Hedge Fund company now holds 106,375 shares of SUPN which is valued at $2,303,019. Supernus Pharmaceuticals Inc makes up approx 0.42% of Franklin Street Advisors Inc Nc’s portfolio.
Supernus Pharmaceuticals Inc closed down -0.31 points or -1.38% at $22.22 with 7,43,985 shares getting traded on Friday. Post opening the session at $22.49, the shares hit an intraday low of $21.875 and an intraday high of $22.69 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.08 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.09. The company had revenue of $43.00 million for the quarter, compared to analysts expectations of $45.32 million. The company’s revenue was up 53.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 18, 2016. Supernus Pharmaceuticals Inc was Downgraded by Northland Capital to ” Market Perform” on Jul 18, 2016.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.